Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.

Cancer investigation - 1 Aug 2026

Heo Ja Yoon, Lee Chung, Shin Heesun, Cho Sungmin, Beom Seung Hoon, Choi Young-Deuk, Han Woong Kyu, Ham Won Sik, Jang Won Sik, Han Hyunho, Lee Jongsoo, Heo Ji Eun, Khalaf Daniel, Emmenegger Urban, Kim Sangwoo, Kim Chang Gon, Jung Minsun, Shin Sang Joon

Abstract excerpt

BACKGROUND: Docetaxel remains a standard treatment for metastatic castration-resistant prostate cancer (mCRPC), yet reliable prognostic markers are lacking. TP53 and RB1, key tumor suppressor genes regulating cell-cycle control and genomic stability, have been linked to aggressive disease and lineage plasticity in advanced prostate cancer. We evaluated the prognostic impact of TP53 and/or RB1 alterations in mCRPC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Progression-Free Survival

Share to Prostatic Neoplasms, Castration-Resistant

Share to Retinoblastoma Binding Proteins

Share to Tumor Suppressor Protein p53

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 42138020
DOI: 10.1080/07357907.2026.2672004

Genes

RB1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.PMID 42138020Read ↗

Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway InhibitorsSemantic proximity Read ↗

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read ↗

Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.Semantic proximity Read ↗

[Clinical features and prognostic value of TP53 mutation in Chinese prostate cancer patients].Semantic proximity Read ↗

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Semantic proximity Read ↗

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.Semantic proximity Read ↗

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressSemantic proximity Read ↗

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.Semantic proximity Read ↗

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.Semantic proximity Read ↗

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.Semantic proximity Read ↗

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.